GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil-Reference-Cited by-同舟云学术

GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil

Published:2021-05-26 Issue:1 Volume:74 Page:146-154
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Manosso Karina Zanlorenzi Basso,Sampaio Carolina Labigalini,Kasuki Leandro,Antunes Ximene,Gadelha Monica R.,Boguszewski Cesar Luiz^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-021-02766-2.pdf

Reference40 articles.

1. M.S. Ben-Shlomo, Acromegaly. Endocrinol. Metab. Clin. N. Am. 37(1), 101–22 (2008). viii

2. C. Capatina, J.A.H. Wass, 60 Years of neuroendocrinology: acromegaly. J. Endocrinol. 226(2), T141–160 (2015)

3. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009)

4. A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, M. Bolanowski, V. Bonert, M.D. Bronstein, F.F. Casanueva, D. Clemmons, A. Colao, D. Ferone, M. Fleseriu, S. Frara, M.R. Gadelha, E. Ghigo, M. Gurnell, A.P. Heaney, K. Ho, A. Ioachimescu, L. Katznelson, F. Kelestimur, J. Kopchick, M. Krsek, S. Lamberts, M. Losa, A. Luger, P. Maffei, M. Marazuela, G. Mazziotti, M. Mercado, P. Mortini, S. Neggers, A.M. Pereira, S. Petersenn, M. Puig-Domingo, R. Salvatori, I. Shimon, C. Strasburger, S. Tsagarakis, A.J. van der Lely, J. Wass, M.C. Zatelli, S. Melmed, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Edocrinol Metab. 105(4), e937–946 (2020)

5. I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89(2), 667–74 (2004)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Biomarkers of response to treatment in acromegaly;Expert Review of Endocrinology & Metabolism;2023-12-11

3. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly;The Journal of Clinical Endocrinology & Metabolism;2022-11-10

4. Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy;Meditsinskiy sovet = Medical Council;2022-06-20